HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
[Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
OBJECTIVE To evaluate clinical efficacy of multiple regimen combination in treatment of osteoporosis of perimenopausal or postmenopausal women . METHODS From Jul. 2008 to Dec. 2009 , 109 women with low bone mineral density ( BMD ) or osteoporosis treated in Department of Obstetrics and Gynecology , Affiliated Second Hospital , Wenzhou Medical College were enrolled r and omly into 3 group , including 36 women in Group A managed by osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid orally , 40 women in group B managed by osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + tibolone 1.25 mg/d orally and 33 women in group C managed by osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + bisphosphonates 70 mg/w orally . After 48 weeks BMD on lumbar 1 - 4 ( L₁₋₄ ) and left femur were detected by X-ray . Bone alkaline phosphatase(BALP ) , cross linked clelopeptide of type I collagen ( CTX ) and 25-hydroxychole calciferol [ 25(OH)D₃ ] was measured by enzyme linked immunosorbent assay ( ELISA ) . RESULT Seven women ( 6.4 % , 7/109 ) were withdrawed form this study , including 2 cases losing follow up in group A , 3 cases stopping treatment in group B , 2 cases giving up treatment due to severe adverse effect ( burning in upper abdomen ) in group C. ( 1 ) Pain relieve : after 48 weeks treatment , women in 3 groups improved symptom of pain significantly , the rates of pain relieve were 85 % ( 29/34 ) in group A , 92 % ( 34/37 ) in group B and 94 % ( 29/31 ) in group C. ( 2 ) BMD : BMD was improved significantly in women in 3 groups after treatment . BMD of L₁₋₄ were ( 0.88 ± 0.15 ) g/cm² in group A , ( 0.89 ± 0.18 ) g/cm² in group B and ( 0.87 ± 0.10 ) g/cm² in group C before treatment , and converted to ( 0.90 ± 0.01 ) g/cm² in group A , ( 0.93 ± 0.09 ) g/cm² in group B and ( 0.91 ± 0.11 ) g/cm² in group C after treatment . BMD of left femur were ( 0.87 ± 0.07 ) g/cm² in group A , ( 0.87 ± 0.07 ) g/cm² in group B and ( 0.85 ± 0.12 ) g/cm² in group C before treatment and converted to ( 0.90 ± 0.03 ) g/cm² in group A , ( 0.91 ± 0.08 ) g/cm² in group B and ( 0.89 ± 0.12 ) g/cm² in group C after treatment . It was shown significantly different BMD between group B or C and group A ( P < 0.01 ) , however , there was no significant different BMD between group B and C ( P > 0.05 ) . ( 3 ) Index of bone metabolism : BALP were ( 26 ± 6 ) µg/L in group A , ( 26 ± 9 ) µg/L in group B and ( 28 ± 7 ) µg/L in group C before treatment and converted to ( 22 ± 5 ) µg/L in group A , ( 20 ± 9 ) µg/L in group B and ( 22 ± 8) µg/L in group C after treatment , which showed statistical difference ( P < 0.05 ) . CTX were ( 0.85 ± 0.20 ) ng/L in group A , ( 0.84 ± 0.47 ) ng/L in group B , and ( 0.88 ± 0.11 ) ng/L in group C before treatment and converted to ( 0.81 ± 0.19 ) ng/L in group A , ( 0.77 ± 0.33 ) ng/L in group B , and ( 0.82 ± 0.14 ) ng/L in group C after treatment , which showed statistical difference ( P < 0.05 ) . CONCLUSIONS Those 3 regimens combination could be used in treatment of osteoporosis by decreasing bone conversion , increasing bone density , decreasing bone absorption . Regimen A was only suitable for basic therapy , the other two regimens could provide better treatment
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .